<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        22-100-95
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1995
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACTRAPID PENFILL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN NEUTRAL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Cartridge
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        103.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Actrapid&reg; is human insulin with a fast-acting effect.</p><p>Actrapid&reg; is used to <strong>reduce the high blood sugar level</strong> in patients with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Treatment with Actrapid&reg; helps to prevent complications from your diabetes.</p><p>Actrapid&reg; will start to lower your blood sugar about half an hour after you inject it, and the effect will last for approximately 8 hours. Actrapid&reg; is often given in combination with intermediate-acting or long-acting insulin preparations.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Actrapid&reg;</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to human insulin or any of the other ingredients in this medicine, see section 6.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suspect hypoglycaemia (low blood sugar) is starting, see <em>Summary of serious and very common side effects</em> in section 4.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In insulin infusion pumps.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the cartridge or the device containing the cartridge is dropped, damaged or crushed.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it has not been stored correctly or if it has been frozen, see section 5.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the insulin does not appear clear and colourless.</p><p>&nbsp;</p><p>If any of these apply, <strong>do not use Actrapid&reg;.</strong> Talk to your doctor, pharmacist or nurse for advice.</p><p>&nbsp;</p><p>Before using Actrapid&reg;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the label to make sure it is the right type of insulin.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always check the cartridge, including the rubber plunger at the bottom of the cartridge. Do not use it if any damage is seen or if the rubber plunger has been drawn above the white label band at the bottom of the cartridge. This could be the result of an insulin leakage. If you suspect that the cartridge is damaged, take it back to your supplier. See your pen manual for further instructions.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use a new needle for each injection to prevent contamination.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Needles and Actrapid&reg; Penfill&reg; must not be shared.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Actrapid&reg; Penfill&reg; is only suitable for injecting under the skin using a reusable pen. Speak to your doctor if you need to inject your insulin by another method.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Some conditions and activities can affect your need for insulin. Consult your doctor:</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are ill, carry on taking your insulin and consult your doctor.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are going abroad, travelling over time zones may affect your insulin needs and the timing hereof.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Skin changes at the injection site</strong></p><p>&nbsp;</p><p>The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p>&nbsp;</p><p><strong>Other medicines and Actrapid&reg;</strong></p><p><strong>Tell your doctor, pharmacist or nurse</strong> if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines affect your blood sugar level, and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.</p><p>&nbsp;</p><p>Your blood sugar level may fall (hypoglycaemia) if you take:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines for the treatment of diabetes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monoamine oxidase inhibitors (MAOI) (used to treat depression)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers (used to treat high blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salicylates (used to relieve pain and lower fever)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anabolic steroids (such as testosterone)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfonamides (used to treat infections).</p><p>&nbsp;</p><p><strong>Your blood sugar level may rise</strong> (hyperglycaemia) if you take:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral contraceptives (birth control pills)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thiazides (used to treat high blood pressure or excessive fluid retention)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticoids (such as &lsquo;cortisone&rsquo; used to treat inflammation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid hormone (used to treat thyroid gland disorders)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sympathomimetics (such as epinephrine [adrenaline], salbutamol or terbutaline used to treat asthma)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body&rsquo;s metabolic processes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Danazol (medicine acting on ovulation).</p><p>&nbsp;</p><p><strong>Octreotide and lanreotide</strong> (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.</p><p>&nbsp;</p><p><strong>Beta-blockers</strong> (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.</p><p>&nbsp;</p><p><strong>Thiazolidinediones</strong> (class of oral antidiabetic medicines used for the treatment of type 2 diabetes)</p><p>Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with thiazolidinediones and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p>&nbsp;</p><p>If you have taken any of the medicines listed here, <strong>tell your doctor, pharmacist or nurse.</strong></p><p>&nbsp;</p><p><strong>Actrapid</strong><strong>&reg; with alcohol</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, ask<strong> </strong>your doctor for advice before taking this medicine. Actrapid&reg; can be used during pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no restrictions on treatment with Actrapid&reg; during breast-feeding.</p><p>&nbsp;</p><p>Ask your doctor, pharmacist or nurse for advice before taking this medicine while pregnant or breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please ask your doctor whether you can drive a car or operate a machine:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have frequent hypoglycaemia.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you find it hard to recognise hypoglycaemia.</p><p>&nbsp;</p><p>If your blood sugar is low or high, it might affect your concentration and ability to react and therefore also your ability to drive or operate a machine. Bear in mind that you could endanger yourself or others.</p><p>&nbsp;</p><p><strong>Actrapid&reg; contains sodium</strong></p><p>Actrapid&reg; contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. Actrapid&reg; is essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dose and when to take your insulin</strong></p><p>Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>Eat a meal or snack containing carbohydrates within 30 minutes of the injection to avoid low blood sugar.</p><p>Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Actrapid&reg; can be used in children and adolescents.</p><p>&nbsp;</p><p><strong>Use in special patient groups</strong></p><p>If you have reduced kidney or liver function, or if you are above 65&nbsp;years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.</p><p>&nbsp;</p><p><strong>How and where to inject</strong></p><p>Actrapid&reg; is administered<strong> by injection under the skin</strong> (subcutaneously). You must never inject yourself directly into a vein (intravenously) or muscle (intramuscularly). Actrapid&reg; Penfill&reg; is only suitable for injecting under the skin using a reusable pen. Speak to your doctor if you need to inject your insulin by another method.</p><p>With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting, see section 4. The best places to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms. The insulin will work more quickly if you inject into the waist (abdomen). You should always measure your blood sugar regularly.</p><p><strong>&nbsp;</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not refill the cartridge. Once empty, it must be disposed of.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Actrapid&reg; Penfill&reg; cartridges are designed to be used with Novo Nordisk insulin delivery systems and NovoFine&reg; or NovoTwist&reg; needles.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are treated with Actrapid&reg; Penfill&reg; and another insulin Penfill&reg; cartridge, you should use two insulin delivery systems, one for each type of insulin.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always carry a spare Penfill&reg; cartridge in case the one in use is lost or damaged.</p><p>&nbsp;</p><p><strong>How to inject Actrapid&reg;</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the insulin<strong> </strong>under your skin.<strong> </strong>Use the injection technique advised by your doctor or nurse and as described in your pen manual.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the needle under your skin<strong> </strong>for at least 6 seconds. Keep the push-button fully depressed until the needle has been withdrawn from the skin. This will ensure correct delivery and limit possible flow of blood into the needle or insulin reservoir.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After each injection,<strong> </strong>be sure to remove and discard the needle and store Actrapid&reg; without the needle attached. Otherwise the liquid may leak out, which can cause inaccurate dosing.</p><p>&nbsp;</p><p><strong>If you take more insulin than you should</strong></p><p>If you take too much insulin your blood sugar gets too low (hypoglycaemia). See <em>Summary of serious and very common side effects</em> in section 4.</p><p>&nbsp;</p><p><strong>If you forget to take your insulin</strong></p><p>If you forget to take your insulin your blood sugar may get too high (hyperglycaemia). See <em>Effects from diabetes</em> in section 4.</p><p>&nbsp;</p><p><strong>If you stop taking your insulin</strong></p><p>Do not stop taking your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis. See <em>Effects from diabetes</em> in section 4.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Summary of serious and very common side effects</strong></p><p>&nbsp;</p><p><strong><em>Low blood sugar (hypoglycaemia)</em></strong><strong> </strong>is a very common side effect. It may affect more than 1 in 10 people.</p><p>&nbsp;</p><p><strong>Low blood sugar may occur if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject too much insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eat too little or miss a meal.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exercise more than usual.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drink alcohol, see <em>Actrapid&reg; with alcohol</em> in section 2.</p><p>&nbsp;</p><p><strong>Signs of low blood sugar:</strong> Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.</p><p>&nbsp;</p><p>Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon by someone who knows how to use it. If you are given glucagon you will need glucose or a sugar snack as soon as you are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital.</p><p>&nbsp;</p><p><strong>What to do if you experience low blood sugar:</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets or high sugar snacks with you, just in case.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When the symptoms of low blood sugar have disappeared or when your blood sugar level is stabilised, continue insulin treatment as usual.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have such low blood sugar that it makes you pass out, if you have had the need for an injection of glucagon, or if you have experienced many incidents of low blood sugar, talk to a doctor. The amount or timing of insulin, food or exercise may need to be adjusted.</p><p>&nbsp;</p><p>Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (becoming unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink, because you may choke.</p><p>&nbsp;</p><p><strong><em>Serious allergic reaction</em></strong> to Actrapid&reg; or one of its ingredients (called a systemic allergic reaction) is a very rare side effect, but it can potentially be life threatening. It may affect less than 1 in 10,000 people.</p><p>&nbsp;</p><p>Seek medical advice immediately:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If signs of allergy spread to other parts of your body.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice any of these signs, seek medical advice immediately.</p><p>&nbsp;</p><p><strong>Skin changes at the injection site</strong>: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect less than 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes</p><p>&nbsp;</p><p><strong>List of other side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Uncommon side effects </em></strong></p><p>May affect less than 1 in 100 people.</p><p>&nbsp;</p><p><strong>Signs of allergy:</strong> Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of taking your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately. See also Serious allergic reactions above.</p><p><strong>&nbsp;</strong></p><p><strong>Vision problems:</strong> When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary.</p><p>&nbsp;</p><p><strong>Swollen joints:</strong> When you start taking insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, talk to your doctor.</p><p>&nbsp;</p><p><strong>Painful neuropathy </strong>(pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain. This is called acute painful neuropathy and is usually transient.</p><p>&nbsp;</p><p><strong><em>Very rare side effects </em></strong></p><p>May affect less than 1 in 10,000 people.</p><p><strong>&nbsp;</strong></p><p><strong>Diabetic retinopathy</strong> (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>Effects from diabetes </strong></p><p>&nbsp;</p><p><strong><em>High blood sugar (hyperglycaemia)</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>High blood sugar may occur if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have not injected enough insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forget to inject your insulin or stop taking insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeatedly inject less insulin than you need.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Get an infection and/or a fever.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eat more than usual.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exercise less than usual.</p><p>&nbsp;</p><p><strong>Warning signs of high blood sugar:</strong></p><p>The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed, dry skin; dry mouth and a fruity (acetone) smell of the breath.</p><p>&nbsp;</p><p><strong>What to do if you experience high blood sugar:</strong></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any of the above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These may be signs of a very serious condition called diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.Do not use this medicine after the expiry date, which is stated on the cartridge label and carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p><strong>Before opening:</strong> Store in a refrigerator at 2&deg;C &ndash; 8&deg;C. Keep away from the cooling element. Do not freeze.</p><p><strong>During use or when carried as a spare:</strong> Do not refrigerate or freeze. You can carry it with you and keep it at room temperature (below 30&deg;C) for up to 6 weeks.</p><p>Always keep the cartridge in the outer carton when you are not using it, in order to protect from light.</p><p>Discard the needle after each injection.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is human insulin. Each ml contains 100 IU of human insulin. Each cartridge contains 300 IU of human insulin in 3 ml solution for injection.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are zinc chloride, glycerol, metacresol, sodium hydroxide, hydrochloric acid and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Actrapid® is presented as a solution for injection. 
Pack sizes of 1, 5 and 10 cartridges of 3 ml. Not all pack sizes may be marketed.

The solution is clear and colourless.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July/ 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">آكت رابِد<sup>&trade;</sup> هو إنسولين بشري سريع المفعول.</p><p dir="RTL">يُستخدم آكت رابِد<sup>&trade;</sup><strong> لتخفيض مستويات السكر في الدم المرتفعة</strong> لدى المرضى المصابين بداء السكري (مرض السكر). ومرض السكري هو مرض يتسبب في عدم قدرة الجسم على إنتاج الإنسولين الكافي للتحكم في مستوى السكر في الدم لديك. يساعد العلاج باستخدام آكت رابِد<sup>&trade;</sup> على تجنب المضاعفات الناتجة عن مرض السكري.</p><p dir="RTL">وسيبدأ آكت رابِد<sup>&trade;</sup> في خفض نسبة السكر في الدم بعد حوالي نصف ساعة من حقن الجرعة، ويستمر تأثيره لمدة 8 ساعات تقريباً. يُستعمل آكت رابِد<sup>&trade;</sup> عادةً مع مستحضرات الإنسولين متوسطة أو طويلة المفعول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم آكت رابِد</strong><sup>&trade;</sup></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من الإنسولين البشري أو أي من المكونات الأخرى لهذا الدواء، انظر القسم 6.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشك في بدء أعراض نقص السكر في الدم (انخفاض مستوى السكر في الدم)، انظر <em>ملخص الآثار الجانبية الخطيرة والشائعة جداً</em> في القسم 4.</p><p dir="RTL"><strong><em>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>في مضخات حقن الإنسولين.</p><p dir="RTL"><strong><em>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>في حالة سقوط أو تلف أو تحطم الخرطوشة أو الجهاز المحتوي على الخرطوشة.</p><p dir="RTL"><strong><em>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>إذا لم يتم تخزين الدواء بشكل صحيح أو إذا تم تجميده، انظر القسم 5.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يظهر شكل الإنسولين صافٍ وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت أيٌ من هذه الحالات تنطبق عليك، <strong>فلا تستخدم دواء آكت رابِد</strong><sup>&trade;</sup>. استشر طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل استعمال آكت رابِد</strong><sup>&trade;</sup><strong> </strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من الملصق للتأكد من أنه النوع الصحيح من الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق دائماً من الخرطوشة، بما في ذلك المكبس المطاطي الموجود في قاع الخرطوشة. لا تستخدم الخرطوشة في حالة رؤية أي تلف بها أو إذا تم إيجاد المكبس المطاطي مسحوباً فوق شريط الملصق الأبيض الموجود في قاع الخرطوشة. حيث قد يكون هذا بسبب تسرب الإنسولين. في حالة الشك في تلف الخرطوشة، قم بإرجاعها إلى المورِّد. اطلع على دليل قلم الحقن للحصول على مزيد من التعليمات.</p><p dir="RTL"><strong><em>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>استخدم دائماً إبرة جديدة<strong> </strong>لكل عملية حقن لمنع التلوث.</p><p dir="RTL"><strong><em>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>يجب عدم مشاركة الإبر وقلم آكت رابِد<strong><em><sup>&trade;</sup></em></strong> بنفل<strong><em><sup>&trade;</sup></em></strong>.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آكت رابِد<sup>&trade;</sup> بنفل<sup>&trade;</sup> مناسب فقط للحقن تحت الجلد باستخدام قلم قابل لإعادة الاستخدام. تحدث إلى طبيبك إذا كنت بحاجة إلى حقن الإنسولين بطريقة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قد تؤثر بعض الظروف والأنشطة على حاجتك للإنسولين. استشِر الطبيب:</p><p dir="RTL"><strong>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من مشكلة في الكليتين أو الكبد أو الغدد الكظرية أو الغدة النخامية أو الغدة الدرقية.</p><p dir="RTL"><strong>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تمارس تمارين رياضية أكثر من المعتاد أو إذا كنت ترغب في تغيير النظام الغذائي الخاص بك، حيث قد يؤثر ذلك على مستوى السكر في الدم.</p><p dir="RTL"><strong>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مريضاً، استمر في استعمال الإنسولين واستشر طبيبك المعالج.</p><p dir="RTL"><strong>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مسافراً خارج البلاد، قد يؤثر السفر إلى المناطق البعيدة على مقدار احتياجك من الإنسولين وتوقيت الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغييرات جلدية في موضع الحقن</strong></p><p dir="RTL">يجب تغيير مكان الحقن في كل مرة لمنع حدوث تغيرات في الأنسجة الدهنية تحت الجلد، مثل زيادة سماكة الجلد أو تقلصه أو تكوَّن كتل تحت الجلد. قد لا يعمل الإنسولين بشكل جيد إذا تم حقنه في مناطق ذات كتل أو مناطق سميكة أو متقلصة (انظر القسم 3 كيفية الاستخدام). اخبر طبيبك عند ملاحظة أي تغييرات في موضع الحقن. اخبر طبيبك إذا كنت تقوم في الوقت الحالي بالحقن في هذه المناطق قبل البدء بالحقن في مناطق أخرى. قد يخبرك طبيبك أن تقوم بفحص سكر دمك بشكل متكرر وأن تعدل جرعتك من الإنسولين أو جرعة الأدوية الفموية الأخرى المخفضة لسكر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وآكت رابِد<sup>&trade;</sup></strong></p><p dir="RTL"><strong>يُرجى إخبار الطبيب أو الصيدلي أو الممرضة</strong> إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى في المستقبل.</p><p dir="RTL">تؤثر بعض الأدوية في مستوى السكر في الدم، وقد يعني هذا ضرورة تغيير جرعة الإنسولين. فيما يلي الأدوية الأكثر شيوعاً التي قد تؤثر في علاجك بالإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد ينخفض مستوى السكر في الدم</strong> (هبوط سكر الدم) إذا أخذت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لعلاج مرض السكري</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أوكسيديز أحادي الأمين (MAOI) (تُستخدم لعلاج الاكتئاب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا (تستخدم لعلاج ارتفاع ضغط الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات الإِنْزيم المُحَوِّل للأنجيوتنسين (ACE) - (تستخدم لعلاج بعض مشاكل القلب أو ضغط الدم المرتفع)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الساليسيلات (تُستخدم لتخفيف الألم وانخفاض الحمى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنشطات البنائية - مثل التيستوستيرون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلفوناميدات (يُستخدم لعلاج الالتهابات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يرتفع مستوى السكر في الدم</strong> (ارتفاع سكر الدم) إذا أخذت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل عن طريق الفم (حبوب منع الحمل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثيازيدات (يُستخدم لعلاج ارتفاع ضغط الدم أو الاحتفاظ المفرط بالسوائل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية القشرانية السكرية (مثل &quot;الكورتيزون&quot; المستخدم لعلاج الالتهابات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون الغدة الدرقية (يُستخدم لعلاج اضطرابات الغدة الدرقية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحاكيات الودية (مثل الإبينيفرين [الأدرينالين]، أو السالبوتامول، أو التيربوتالين المستخدم لعلاج الربو)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون النمو (دواء لتحفيز الهيكل العظمي والنمو الجسدي وله تأثير واضح على عمليات التمثيل الغذائي في الجسم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانازول (دواء يؤثر على الإباضة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي <strong>أوكتوريوتيد ولانريوتيد</strong> (يستخدمان لعلاج ضخامة الأطراف، وهو اضطراب هرموني نادر يحدث عادة عند البالغين في منتصف العمر، وينتج عن إنتاج الغدة النخامية لهرمون النمو الزائد) إلى زيادة أو نقصان مستوى السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تضعف <strong>حاصرات بيتا</strong> (تُستخدم لعلاج ارتفاع ضغط الدم) أو تكبح تماماً أعراض التحذير الأولى التي تساعدك على التعرّف على نقص مستوى السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ثيازوليدينديون</strong> (فئة من الأدوية المضادة للسكري يتم تناولها عن طريق الفم وتُستخدم لعلاج داء السكري من النوع الثاني)</p><p dir="RTL">بعض المرضى المصابين بالنوع الثاني من داء السكري وأمراض القلب لفترات طويلة أو المصابين بسكتة دماغية سابقاً، والذين عولجوا بأدوية ثيازوليدينديون مع الإنسولين، تعرّضوا إلى الإصابة بقصور في القلب. فاحرص على إبلاغ الطبيب المعالج في أقرب وقت ممكن إذا كنت تعاني من علامات قصور في القلب مثل ضيق التنفس غير العادي أو زيادة الوزن السريعة أو التورم الموضعي (وذمة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد أخذت أي من الأدوية الواردة هنا، <strong>أخبر الطبيب أو الصيدلي أو الممرضة</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آكت رابِد<sup>&trade;</sup> مع الكحول</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الكحول، فقد تتغير حاجتك للإنسولين لأن مستوى السكر في الدم قد يرتفع أو ينخفض. ولذلك يوصى بالمراقبة الدقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً، أو تعتقدين أنكِ حامل أو تنوين الحمل،<strong> </strong>فاستشيري طبيبك قبل أخذ هذا الدواء. يمكن استخدام آكت رابِد<sup>&trade;</sup> خلال فترة الحمل. قد يلزم تغيير جرعة الإنسولين أثناء الحمل وبعد الولادة. ويعد التحكم الدقيق بمرض السكري، وخاصة الوقاية من نقص سكر الدم، أمراً هاماً لصحة طفلك.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا توجد أي قيود على العلاج بآكت رابِد<sup>&trade;</sup> أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري الطبيب أو الصيدلي أو الممرضة قبل تناول هذا الدواء أثناء الحمل أو الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يرجى سؤال الطبيب عما إذا كان بإمكانك قيادة سيارة أو تشغيل آلة في الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص سكر الدم بشكل متكرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجدت صعوبة في التعرف على نقص سكر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان مستوى السكر في الدم منخفضاً أو مرتفعاً، فقد يؤثر ذلك على تركيزك وقدرتك على التصرف، وبالتالي قدرتك على القيادة أو تشغيل الآلات. فيرجى الانتباه إلى أنك قد تعرض نفسك أو الآخرين للخطر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي آكت رابِد<sup>&trade;</sup> على الصوديوم</strong></p><p dir="RTL">يحتوي آكت رابِد<sup>&trade;</sup> على أقل من 1 ميليمول من الصوديوم (23 ملجم) لكل جرعة، &rlm;‫وهذا يعني أن آكت رابِد<sup>&trade;</sup> &quot;خالٍ من الصوديوم&quot; تقريباً.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جرعة الإنسولين وموعدها </strong></p><p dir="RTL">يجب دوماً استخدام الإنسولين وضبط جرعتك كما أخبرك الطبيب تماماً. ويجب استشارة الطبيب أو الصيدلي أو الممرضة في حالة الشك بشأن طريقة استخدامه على الوجه الصحيح.</p><p dir="RTL">واحرص على تناول وجبة خفيفة أو وجبة تحتوي على الكربوهيدرات في غضون 30 دقيقة من الحقن لتجنب نقص السكر في الدم.</p><p dir="RTL">ولا تغير نوع الإنسولين، إلا إذا أخبرك طبيبك بذلك. وإذا نصحك الطبیب المعالج بتغيير نوع الإنسولین إلی آخر، قد یتعین علیك ضبط الجرعة مع طبیبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استعماله للأطفال والمراهقين</strong></p><p dir="RTL">يمكن استعمال آكت رابِد<sup>&trade;</sup> للأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال مع فئات خاصة من المرضى</strong></p><p dir="RTL">إذا كنت تعاني من انخفاض وظائف الكلى أو الكبد أو كان عُمرك يزيد على 65 سنة، يجب عليك التحقق من نسبة السكر في الدم بشكل أكثر انتظاماً ومناقشة تغيرات جرعة الإنسولين مع طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية ومكان الحقن</strong></p><p dir="RTL">يُؤخذ آكت رابِد<sup>&trade;</sup><strong> بالحقن تحت الجلد</strong>. يحظر تماماً حقن نفسك بالإنسولين مباشرةً في الوريد أو في العضل. آكت رابِد<sup>&trade;</sup> بنفل<sup>&trade;</sup> مناسب فقط للحقن تحت الجلد باستخدام قلم قابل لإعادة الاستخدام. تحدث إلى طبيبك إذا كنت بحاجة إلى حقن الإنسولين بطريقة أخرى.</p><p dir="RTL">ومع كل حقنة يجب تغيير موضع الحقن في منطقة معينة من الجلد. &rlm;‫فقد يقلل هذا من خطر تكون الكتل أو تورم الجلد، انظر القسم 4. &rlm;‫أفضل أماكن للحقن هي الجزء الأمامي من الخصر (البطن) الأرداف ومقدمة الفخذ والجزء العلوي من الذراعين. وسيعمل الإنسولين بسرعة أكبر إذا قمت بحقنه في الخصر (البطن). ولا تنسى قياس مستوى السكر في الدم بانتظام دائماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بإعادة ملء الخرطوشة. فبمجرد أن يفرغ، يجب التخلص منه.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تصميم خراطيش آكت رابِد<sup>&trade;</sup> بنفل<sup>&trade;</sup> لاستخدامها مع أجهزة حقن الإنسولين من Novo Nordisk وإبر نوفوفاين<sup>&trade;</sup> أو نوفوتويست<sup>&trade;</sup>.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفي حال كنت تُعالَج باستعمال آكت رابِد<sup>&trade;</sup> بنفل<sup>&trade;</sup> وخرطوشة إنسولين بنفل<sup>&trade;</sup> أخرى، يجب عليك استخدام اثنين من أنظمة إعطاء الإنسولين، واحداً لكل نوع من الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص دائماً على حمل خرطوشة بنفل<sup>&trade;</sup> احتياطية، تحسباً لفقدان أو تلف الخرطوشة الجاري استعمالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية حقن آكت رابِد<sup>&trade;</sup></strong></p><p dir="RTL"><strong>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>احقن الإنسولين تحت الجلد.<strong> </strong>واتبع طريقة الحقن التي أوصى بها الطبيب أو الممرضة وفقاً لما هو موضح في دليل قلم الحقن.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك الإبرة تحت جلدك لمدة 6 ثوانٍ على الأقل. استمر في الضغط على الزر بشكل كامل إلى أن يتم سحب الإبرة من الجلد. فهذا من شأنه أن يضمن الحقن الصحيح مع الحد من تدفق الدم في الإبرة أو خزان الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد كل عملية حقن،<strong> </strong>تأكد من إزالة الإبرة والتخلص منها وتخزين آكت رابِد<sup>&trade;</sup> بدون الإبرة المرفقة. وإلا فقد يتسرب السائل، مما يؤدي إلى الحصول على جرعات غير دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استعمال كمية إنسولين أكبر مما ينبغي</strong></p><p dir="RTL">في حال استعمال الكثير من الإنسولين، ستنخفض نسبة السكر في الدم جداً (هبوط سكر الدم). انظر <em>&rlm;‫ملخص الآثار الجانبية الخطيرة والشائعة جداً</em> في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان استعمال الإنسولين</strong></p><p dir="RTL">إذا نسيت أخذ جرعة الإنسولين، فقد يرتفع مستوى السكر في الدم أكثر من اللازم (زيادة جلوكوز الدم). انظر <em>آثار ناشئة عن داء السكري</em> في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استعمال الإنسولين</strong></p><p dir="RTL">لا تتوقف عن استعمال الإنسولين دون التحدث إلى الطبيب الذي سيخبرك بما يجب القيام به. قد يؤدي ذلك إلى ارتفاع حاد في مستوى السكر في الدم (ارتفاع شديد في نسبة السكر في الدم) والحماض الكيتوني. انظر <em>آثار ناشئة عن داء السكري</em> في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، ينبغي استشارة طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;‫ملخص الآثار الجانبية الخطيرة والشائعة جداً</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من الآثار الجانبية الشائعة جداً <strong><em>انخفاض مستوى السكر في الدم (نقص مستوى السكر في الدم)</em></strong>. حيث يمكن أن يصيب أكثر من شخص من كل 10 أشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث انخفاض السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم حقن جرعة زائدة من الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولت كمية من الطعام أقل من اللازم أو لم تتناول إحدى الوجبات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمرنت أكثر من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫شربت الكحول، انظر <em>&rlm;آكت رابِد<sup>&trade;</sup> مع الكحول</em> في القسم 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات نقص السكر في الدم:</strong> التعرق البارد؛ شحوب الجلد وبرودته؛ صداع؛ سرعة ضربات القلب؛ الشعور بالمرض؛ الشعور بالجوع المفرط؛ تغييرات مؤقتة في الرؤية؛ الشعور بالنعاس؛ الشعور بالتعب والضعف بشكل غير عادي؛ التوتر أو الرعشة؛ الشعور بالقلق؛ الشعور بالارتباك؛ صعوبة التركيز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي الانخفاض الحاد في مستوى السكر في الدم إلى فقدان الوعي. وإذا لم يتم علاج الانخفاض الحاد في مستوى السكر في الدم لفترة طويلة، قد يتسبب ذلك في تلف المخ (مؤقت أو دائم) أو حتى الوفاة. قد تتعافى بسرعة أكبر من حالة فقدان الوعي عن طريق حقنة هرمون الجلوكاجون بواسطة شخص يعرف كيفية استخدامها. وإذا كنت تستعمل الجلوكاجون، ستحتاج إلى تناول الجلوكوز أو وجبة خفيفة سكرية بمجرد الرجوع إلى وعيك. وإذا لم تستجيب لحقن الجلوكاجون، يجب أن تذهب للمستشفى للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله في حالة انخفاض مستوى السكر في الدم:</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة انخفاض مستوى السكر في الدم، يجب عليك تناول أقراص الجلوكوز أو غيرها من الوجبات الخفيفة عالية السكر (الحلويات أو البسكويت أو عصير الفاكهة). ينبغي قياس مستوى السكر في الدم وأخذ قسط من الراحة. ولذلك ينبغي دائماً الاحتفاظ بأقراص الجلوكوز أو الوجبات الخفيفة عالية السكر معك من باب الاحتياط.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تختفي أعراض انخفاض مستوى السكر في الدم أو عند استقرار مستوى السكر في الدم، واصل العلاج المعتاد بالإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستوى السكر في الدم لدرجة فقدان الوعي، أو إذا احتجت إلى حقن الجلوكاجون أو إذا كنت قد تعرضت للعديد من حالات انخفاض مستوى السكر في الدم، عليك استشارة طبيبك. حيث قد يلزم تعديل كمية الإنسولين أو توقيت أخذ الجرعة أو كمية الطعام المتناول أو التمارين الرياضية الممارسة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الأشخاص ذوي الصلة أنك مصاب بمرض السکري وأطلعهم على العواقب التي قد تحدث لك، بما في ذلك خطر فقدان الوعي بسبب نقص مستوى السكر في الدم. أخبرهم أنه في حال فقدانك للوعي، يجب عليهم إسنادك إلى جانبك والحصول على المساعدة الطبية على الفور. ولا يجب أن يعطوك أي طعام أو شراب لأنه قد ينحشر في حلقك ويصيبك بالاختناق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>التفاعل التحسسي الخطير</em></strong> لدواء آكت رابِد<sup>&trade;</sup> أو أحد مكوناته (يسمى التفاعل التحسسي الجهازي) هو من الأعراض الجانبية النادرة جداً، ولكن قد يكون مهدداً للحياة. حيث يمكن أن يصيب أقل من شخص من كل 10000 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلب المشورة الطبية فوراً:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انتشرت علامات الحساسية إلى أجزاء أخرى من جسمك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت فجأة بأنك ليست على ما يرام و: بدأت في التعرق أو في المرض (القيء) أو وجدت صعوبة التنفس أو شعرت بسرعة ضربات القلب أو بالدوار.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت وجود أي من هذه العلامات، فاطلب المشورة الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغييرات جلدية في موضع الحقن: </strong>إذا كنت تقوم بحقن الإنسولين كل مرة في نفس المكان، قد تتقلص الأنسجة الدهنية تحت الجلد في موضع الحقن (الحثل الشحمي) أو تتضخم (التكتل الشحمي) (قد تؤثر في أقل من شخص واحد في كل 100 شخص). قد تتكوَّن الكتل تحت الجلد بسبب تراكم البروتين بما يسمى الداء النشواني ( النشواني الجلدي, معدل التكرار غير معروف). قد لا يعمل الإنسولين بشكل جيد إذا تم حقنه في مناطق ذات كتل أو مناطق سميكة أو متقلصة. قم بتغيير مكان الحقن في كل مرة لمنع حدوث مثل هذه التغييرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قائمة بآثار جانبية أخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية غير الشائعة </em></strong></p><p dir="RTL">يمكن أن تصيب أقل من شخص من كل 100 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات حدوث الحساسية:</strong> تفاعلات الحساسية الموضعية (شعور بألم، احمرار، شَرَى، التهاب، كدمات، تورم، حكة) في موضع الحقن. وعادةً ما تختفي هذه التفاعلات بعد بضعة أسابيع من استعمال الإنسولين. إذا لم تختفي الأعراض أو إذا انتشرت في جميع أنحاء جسمك، تحدث إلى طبيبك على الفور. انظر كذلك &rlm;‫علامات تفاعلات الحساسية الخطيرة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;‫مشاكل الرؤية:</strong> عندما تبدأ أول جرعة علاج بالإنسولين، قد تصاب بمشاكل في الرؤية، ولكن عادة ما يكون ذلك الاضطراب مؤقتاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;‫تورم المفاصل:</strong> عند بدء استعمال الإنسولين، قد يسبب احتباس الماء حدوث تورم حول الكاحلين والمفاصل الأخرى. وعادة هذا يختفي ذلك قريباً. ولكن إذا لم تختفي الأعراض، ينبغي استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;‫الاعتلال العصبي المؤلم</strong> (ألم ناتج عن تلف الأعصاب) إذا تطوَّر مستوى السكر في الدم بشكل سريع جداً، فقد تشعر بألم مرتبط بالأعصاب. وهذا ما يسمى بالاعتلال العصبي المؤلم الحاد، وعادة ما يكون عابراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية النادرة جداً </em></strong></p><p dir="RTL">يمكن أن تصيب أقل من شخص من كل 10000 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اعتلال الشبكية السكري&rlm;‫</strong> &rlm;‫(مرض بالعين مرتبط بمرض السكري والذي يمكن أن يؤدي إلى فقدان الرؤية). &rlm;‫إذا كنت تعاني من اعتلال الشبكية السكري مع تطور مستوى السكر في الدم بسرعة كبيرة، قد يزداد اعتلال الشبكية سوءاً. ولذلك يجب استشارة الطبيب المعالج في هذا الشأن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرضة. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة. فبالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;‫آثار ناشئة عن داء السكري </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>ارتفاع السكر في الدم (فرط جلوكوز الدم)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث ارتفاع السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تحقن جرعة كافية من الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسيت حقن الإنسولين أو توقفت عن تناول الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقنت كمية إنسولين أقل مما تحتاج إليه بشكل متكرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت بالعدوى و/أو الحمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكلت كمية أكبر من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمرنت أقل من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&rlm;‫<strong>العلامات التحذيرية لارتفاع مستوى السكر في الدم:</strong></p><p dir="RTL">تظهر العلامات التحذيرية تدريجياً. وتشمل: زيادة التبول؛ الشعور بالعطش؛ فقدان الشهية؛ الشعور بالمرض (الغثيان أو القيء)؛ الشعور بالنعاس أو التعب، الشعور بالحرارة، جفاف الجلد؛ جفاف الفم ورائحة نفس أشبه بالفاكهة (أسيتون).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله في حالة حدوث ارتفاع شديد في مستوى السكر في الدم لديك:</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فإذا كنت تعاني من أي من العلامات الواردة أعلاه، اختبر مستوى السكر في الدم لديك، واختبر البول لمعرفة الكيتونات في حالة الاستطاعة، ثم اطلب المشورة الطبية على الفور.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشير هذه العلامات إلى حالة خطيرة جداً تسمى الحماض الكيتوني السكري (تراكم الحمض في الدم لأن الجسم يكسر الدهون بدلاً من السكر). وإذا لم تعالج هذه الحالة، قد تؤدي إلى الدخول في غيبوبة سكر والوفاة في أخر الأمر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على ملصق الخرطوشة والعلبة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL"><strong>قبل الفتح:</strong> يُخزن في الثلاجة في درجة حرارة 2 إلى 8 درجات مئوية. يُحفظ بعيداً عن عنصر التبريد. يُراعى عدم التجميد.</p><p dir="RTL"><strong>أثناء الاستخدام أو عند الاحتفاظ بالدواء كعبوة بديلة:</strong> لا يوضع في الثلاجة ولا يُجمد. بل يمكنك حملها معك وحفظها في درجة حرارة الغرفة (أقل من 30 درجة مئوية) لمدة تصل إلى 6 أسابيع.</p><p dir="RTL">احرص دائماً على وضع الخرطوشة في العبوة الكرتونية الخارجية في حالة عدم استخدامها، من أجل حمايتها من الضوء.</p><p dir="RTL">يجب التخلص من الإبرة بعد كل عملية حقن.</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي الإنسولين البشري. يحتوي كل &nbsp;مل على 100 وحدة دولية من الإنسولين البشري. تحتوي كل خرطوشة على 300 وحدة من الإنسولين البشري لكل 3 مل من المحلول للحقن.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي كلوريد الزنك والجلسرين والميتاكرسول وهيدروكسيد الصوديوم وحمض الهيدروكلوريك وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر آكت رابِد<sup>&trade;</sup> على شكل محلول للحقن.</p><p dir="RTL">تحتوي العبوات على خرطوشة واحدة أو 5 أو 10 خرطوشات بحجم 3 مل. لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتميز المحلول بأنه صافٍ وعديم اللون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو /2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Actrapid Penfill 100 international units/ml solution for injection in cartridge.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Actrapid Penfill
1 cartridge contains 3 ml equivalent to 300 international units. 1 ml solution contains 100 international
units insulin human* (equivalent to 3.5 mg).

*Human insulin is produced in Saccharomyces cerevisiae by recombinant DNA technology.
Excipient with known effect:
Actrapid contains less than 1 mmol sodium (23 mg) per dose, i.e. Actrapid is essentially ‘sodiumfree’.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
The solution is clear, colourless and aqueous.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Actrapid is indicated for treatment of diabetes mellitus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The potency of human insulin is expressed in international units</p><p>Actrapid dosing is individual and determined in accordance with the needs of the patient. It can be used alone or in combination with intermediate-acting or long-acting insulin before a meal or a snack.</p><p>The individual insulin requirement is usually between 0.3 and 1.0 international unit/kg/day.<br />Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.</p><p>Special populations<br />Elderly (&ge; 65 years old)<br />Actrapid can be used in elderly patients.<br />In elderly patients, glucose monitoring should be intensified and the insulin dose adjusted on an individual basis.</p><p><br />Renal and hepatic impairment<br />Renal or hepatic impairment may reduce the patient&rsquo;s insulin requirements.<br />In patients with renal or hepatic impairment, glucose monitoring should be intensified and the human insulin dose adjusted on an individual basis.</p><p><br />Paediatric population<br />Actrapid can be used in children and adolescents.</p><p><br />Transfer from other insulin medicinal products<br />When transferring from other insulin medicinal products, adjustment of the Actrapid dose and the dose of the basal insulin may be necessary.</p><p><br />Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).</p><p><br />Method of administration<br />Actrapid is a fast-acting human insulin and may be used in combination with intermediate or longacting insulin medicinal products.</p><p><br />Actrapid is administered subcutaneously by injection in the abdominal wall, the thigh, the gluteal region or the deltoid region. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8). Injection into a lifted skin fold minimises the risk of unintended intramuscular injection.</p><p><br />The needle should be kept under the skin for at least 6 seconds to make sure the entire dose is injected.<br />Subcutaneous injection into the abdominal wall ensures a faster absorption than other injection sites.<br />The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.</p><p><br />An injection should be followed within 30 minutes by a meal or snack containing carbohydrates.</p><p><br />Due to the risk of precipitation in pump catheters, Actrapid should not be used in insulin pumps for continuous subcutaneous insulin infusion.</p><p><br />Actrapid vial (40 international units/ml)/Actrapid vial (100 international units/ml)<br />Intravenous use</p><p><br />If necessary, Actrapid can be administered intravenously. This should be carried out by healthcare professionals.</p><p>For intravenous use, infusion systems with Actrapid at concentrations from 0.05 international unit/ml to 1.0 international unit/ml human insulin in the infusion fluids 0.9% sodium chloride, 5% dextrose and 10% dextrose with 40 mmol/l potassium chloride using polypropylene infusion bags, are stable at<br />room temperature for 24 hours. Although stable over time, a certain amount of insulin will initially be adsorbed to the material of the infusion bag. Monitoring of blood glucose is necessary during the insulin infusion.</p><p><br />For detailed user instructions, please refer to the package leaflet.</p><p><br />Actrapid vial (40 international units/ml)/Actrapid vial (100 international units/ml)<br />Administration with a syringe Actrapid vials are for use with insulin syringes with a corresponding unit scale. When two types of insulin are mixed always mix the insulin medicinal products in the same sequence.</p><p><br />Actrapid Penfill<br />Administration with an insulin delivery system</p><p>Actrapid Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. Actrapid Penfill is only suitable for subcutaneous injections from a reusable pen.<br />If administration by syringe or intravenous injection is necessary, a vial should be used.</p><p>Actrapid InnoLet<br />Administration with InnoLet<br />Actrapid InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. InnoLet delivers 1-50 units in increments of 1 unit. Actrapid InnoLet is only suitable for subcutaneous injections. If administration by syringe or intravenous injection is necessary, a vial should be used.</p><p><br />Actrapid FlexPen<br />Administration with FlexPen<br />Actrapid FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1-60 units in increments of 1 unit. Actrapid FlexPen is only suitable for subcutaneous injections. If administration by syringe or intravenous injection is necessary, a vial should be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before travelling between different time zones, the patient should seek the doctor&rsquo;s advice since this may mean that the patient has to take the insulin and meals at different times.</p><p><br />Hyperglycaemia<br />Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually, the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath.<br />In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.</p><p><br />Hypoglycaemia<br />Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia.</p><p>ypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected, Actrapid must not be injected. After stabilisation of the patient&rsquo;s blood glucose, adjustment of the dose should be considered (see sections 4.8 and 4.9).</p><p><br />Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.</p><p><br />Concomitant illness, especially infections and feverish conditions, usually increases the patient&rsquo;s insulin requirement. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.</p><p><br />When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.</p><p><br />Transfer from other insulin medicinal products<br />Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal insulin, human insulin or insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in a need for a change in dose. Patients transferred to Actrapid from another type of insulin may<br />require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.</p><p><br />Injection site reactions<br />As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of Actrapid.</p><p><br />Skin and subcutaneous tissue disorders<br />Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia.<br />Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.</p><p><br />Combination of Actrapid with pioglitazone<br />Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Actrapid is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema.<br />Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</p><p><br />Avoidance of accidental mix-ups/medication errors<br />Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Actrapid and other insulin products.</p><p><br />Traceability</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of medicinal products are known to interact with glucose metabolism.</p><p><br />The following substances may reduce the patient&rsquo;s insulin requirement:<br />Oral antidiabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulfonamides.</p><p><br />The following substances may increase the patient&rsquo;s insulin requirement:<br />Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.<br />Beta-blockers may mask the symptoms of hypoglycaemia.</p><p><br />Octreotide/lanreotide may either increase or decrease the insulin requirement.</p><p><br />Alcohol may intensify or reduce the hypoglycaemic effect of insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier.</p><p><br />Both hypoglycaemia and hyperglycaemia, which can occur in inadequately controlled diabetes therapy, increase the risk of malformations and death in utero. Intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimesters. After delivery, insulin requirements normally<br />return rapidly to pre-pregnancy values.</p><p>Breast-feeding<br />There is no restriction on treatment with Actrapid during breast-feeding. Insulin treatment of the nursing mother presents no risk to the baby. However, the Actrapid dose may need to be adjusted.</p><p><br />Fertility<br />Animal reproduction studies with human insulin have not revealed any adverse effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p><p><br />Patients should be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most frequently reported adverse reaction during treatment is hypoglycaemia. The frequencies of hypoglycaemia vary with patient population, dose regimens and level of glycaemic control, please see Description of selected adverse reactions below.</p><p><br />At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur.<br />These reactions are usually of a transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.</p><p><br />Tabulated list of adverse reactions<br />The adverse reactions listed below are based on clinical trial data and classified according to MedDRA frequency and System Organ Class. Frequency categories are defined according to the following convention: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><img alt="" width="608" height="415" src="data:image/png;base64,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" />Description of selected adverse reactions<br />Anaphylactic reactions<br />The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulty in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life threatening.</p><p><br />Hypoglycaemia<br />The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.</p><p>The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentrating, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.<br />In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control.</p><p><br />Skin and subcutaneous tissue disorders<br />Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</p><p><br />Paediatric population<br />Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general population.</p><p><br />Other special populations<br />Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.</p><p><br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p><br />Please report adverse drug events to</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A specific overdose of insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high a dose relative to the patient&rsquo;s requirement is administered:<br />&bull; Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar-containing products.<br />&bull; Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes.<br />Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, fast-acting, insulin (human). ATC code: A10AB01.</p><p><br />Mechanism of action and pharmacodynamic effects<br />The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.</p><p><br />A clinical trial in a single intensive care unit treating hyperglycaemia (blood glucose above 10 mmol/l) in 204 diabetic and 1344 non-diabetic patients undergoing major surgery showed that normoglycaemia (blood glucose 4.4 &ndash; 6.1 mmol/l) induced by intravenous Actrapid reduced mortality by 42% (8% versus 4.6%).</p><p><br />Actrapid is a fast-acting insulin.<br />Onset of action is within &frac12; hour, reaches a maximum effect within 1.5&ndash;3.5 hours and the entire duration of action is approximately 7&ndash;8 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insulin in the blood stream has a half-life of a few minutes. Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics.</p><p>This process is influenced by several factors (e.g. insulin dose, injection route and site, thickness of subcutaneous fat, type of diabetes). The pharmacokinetics of insulin medicinal products are therefore affected by significant intra- and inter-individual variation.</p><p><br />Absorption<br />The maximum plasma concentration is reached within 1.5&ndash;2.5 hours after subcutaneous administration.</p><p><br />Distribution<br />No profound binding to plasma proteins, except circulating insulin antibodies (if present) has been observed.</p><p><br />Metabolism<br />Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase. A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.</p><p><br />Elimination<br />The terminal half-life is determined by the rate of absorption from the subcutaneous tissue. The terminal half-life (t&frac12;) is therefore a measure of the absorption rather than of the elimination per se of insulin from plasma (insulin in the blood stream has a t&frac12; of a few minutes). Trials have indicated a t&frac12; of about 2-5 hours.</p><p><br />Paediatric population<br />The pharmacokinetic profile of Actrapid has been studied in a small number (n=18) of diabetic children (aged 6&ndash;12 years) and adolescents (aged 13&ndash;17 years). The data are limited but suggest that the pharmacokinetic profile in children and adolescents may be similar to that in adults. However,&nbsp;there were differences between age groups in Cmax, stressing the importance of individual dose titration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinc chloride<br />Glycerol<br />Metacresol<br />Sodium hydroxide (for pH adjustment)<br />Hydrochloric acid (for pH adjustment)<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insulin medicinal products should only be added to compounds with which it is known to be compatible. Medicinal products added to the insulin solution may cause degradation of the insulin, e.g. if the medicinal products contain thiols or sulfites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before opening: 30 months.

Actrapid Penfill/Actrapid InnoLet/Actrapid FlexPen
During use or when carried as a spare: The product can be stored for a maximum of 6 weeks. Store below 30°C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before opening: Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>Actrapid Penfill<br />During use or when carried as a spare: Store below 30&deg;C. Do not refrigerate or freeze.<br />Keep the cartridge in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Actrapid Penfill<br />Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene)<br />containing 3 ml of solution.<br />Pack sizes of 1, 5 and 10 cartridges. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use this medicinal product if you notice that the solution is not clear, colourless and aqueous.<br />Actrapid which has been frozen must not be used.<br />The patient should be advised to discard the needle and syringe after each injection.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<br />Needles, syringes, cartridges and pre-filled-pens must not be shared.<br />The cartridge must not be refilled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>